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Abstract
Background
Patients with end-stage renal disease have very high mortality. In individuals on hemodialy-
sis, cardiovascular deaths account for ~50% of all deaths in this population, mostly due to
arrhythmia. To determine the causes of these arrhythmic deaths is essential in order to
adopt preventive strategies. The main objective of this study was to investigate whether, the
presence of QTc interval alterations, from electrolyte abnormalities or presence of rare
genetic variants, could have a relationship with sudden arrhythmogenic deaths in end-stage
renal disease patients.
Methods
We recorded the pre- and post-dialysis QTc interval in 111 patients undergoing hemodialy-
sis. In 47 of them, we analyzed 24 SCD-related genes including the most prevalent genes
associated with long QT syndrome using a custom resequencing panel.
Results
We found a positive although not significant association between the presence of long QTc
and mortality in a subset of end-stage renal disease patients. In addition, in five patients with
long QTc only after dialysis (21.7%) we detected rare potentially pathogenic genetic vari-
ants. Three out of these five carriers subsequently died suddenly.
Conclusions
Genetic background may be determinant in the risk of sudden cardiac death in these
patients. We recommend evaluating the QTc interval before and after hemodialysis, and
performing a genetic analysis of individuals with long QTc after hemodialysis.
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Introduction
Chronic kidney disease (CKD), defined as either kidney damage or glomerular filtration rate
(GFR) below 60ml/min/1.73m2 for 3 months[1], is a very relevant health entity. CKD has a
prevalence of 4.7–8.1% in people ages 60 and older and of 0.5%, in the population between the
ages of 20 and 39 years of age [2, 3]. People with CKD are at higher mortality risk compared
with the general population. In fact, cardiovascular deaths (CD) account for ~50% of all deaths
in CKD, particularly in individuals on hemodialysis (HD)[4]. Most cardiovascular deaths in
this patient population involves arrhythmic mechanisms[5]. The risk factors predisposing to
sudden cardiac death (SCD) include low concentration of potassium in the dialysate, diabetes
mellitus, advanced age, and undergoing dialysis session after the weekend break[6].
In some studies have reported that HD sessions may induce altered ventricular repolariza-
tion with QTc interval prolongation, which could be a potential arrhythmic risk for these
patients [7]. The QTc interval prolongation in CKD may be induced by electrolyte level alter-
ation. Thus, in end-stage renal disease (ESRD), prolongation of the QTc interval has always
been believed related to changes in serum potassium, magnesium, calcium and phosphate lev-
els during HD[7, 8], and specially linked to the composition of the hemodialysis bath, since
the longest QTc interval duration occurs with low-potassium and low calcium dialysate[9].
However, long QTc intervals could also be caused by a combination of electrolyte and genetic
factors, as it is well known that genetic variants in genes encoding ion channels may be respon-
sible for QTC alterations and long QT Syndrome (LQTS). However, investigation of a genetic
background potentially predisposing to long QT in ESRD has yet to be performed.
Thus, in order to further understand the mechanisms leading to arrhythmogenicity in HD
patients we aim at investigating the QTc interval in ESRD patients both before and after HD,
and its relation with the presence of rare genetic variants associated with LQTS.
Materials and methods
Sample selection and clinical data
The patients included in this study were selected from a cohort of patients treated for CKD at
the Nephrology Department of Marque´s de Valdecilla University Hospital (Santander, Spain).
We included all outpatients (N = 143) undergoing HD therapy between May, 2011 and July,
2012 at the Nephrology Service of the Marques de Valdecilla University Hospital. All patients
had a GFR of<15ml/min/1.73m2. We excluded individuals who were taking drugs known to
prolong the QT interval, and those who had a pacemaker, bundle branch block or atrial fibril-
lation. Thirty-two of 143 patients met the exclusion criteria (22.38%), so 111 patients were
finally included in the study (77.62%). We recorded the following demographic and clinical
parameters: age, gender, race, height, weight, time on HD, disease etiology, classical cardiovas-
cular risk factors, and cardiovascular and coronary events. Patients were followed up until
December, 2014.
This study was approved by the Institutional Human Research Review Board of the Hospi-
tal, was performed conform the declaration of Helsinki and all patients gave written informed
consent to be included.
Dialysis
We performed haemodiafiltration with High Flux Helixone (Fresenius Medical Care, Ger-
many) for four hours per session, with a mean blood flow 350 ± 40 mL/min and mean weight
loss of 2.1 ± 0.3 Kg. All patients were treated with a dialysis regimen of bicarbonate dialysis
with the following electrolyte composition in the bath (mmol/L): 140 Na+, 1.5 K+, 1.25 Ca2+,
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0.5 Mg2+. Drug therapy was allowed during hemodialysis, with the exception of isotonic saline
infusion and sodium heparin.
Electrocardiographic assessment
All enrolled patients underwent a resting, high-quality 12-lead ECG recording before and after
the HD session in a standard setting (EGC recorder Cardiosoft model V6.0 with a CAM-14
module). The QT interval was measured by the investigators for each patient and was cor-
rected for patient heart rate using Bazett’s formula: QTc = QT/
p
RR (ms), where QTc is the
corrected value of the QT interval. ECG was recorded for a single HD session per patient. The
recorded ECG was only used if the HD session took place without any unusual incidents and if
the patient had been free of interfering factors (drugs affecting QT, fever, diarrhea, vomiting)
for the previous 24 hours.
The patients were classified in four groups depending on the QTc value before and after
HD. A QTc of>460ms was considered prolonged[10]. Group 1, NNQTc (Normal-Normal
QTc), included patients without prolonged QTc before or after the HD; Group 2, NLQTc
(Normal-Long QTc), included patients with normal QTc before and prolonged QTc after HD;
Group 3, LNQTc (Long-Normal QTc), included patients with prolonged QTc before and nor-
mal after HD; and Group 4, LLQTc (Long-Long QTc), included patients with a long QTc both
before and after HD.
Laboratory analysis
A venous blood sample was drawn by phlebotomy immediately before and after HD sessions,
collected in a sterile tube, placed immediately on ice, centrifuged on site within 90 min and
frozen at -20˚C. We quantified serum sodium, potassium, calcium, and magnesium ion con-
centrations using an ABL80 FLEX analyzer (Radiometer, Iberia). The following values were
considered normal: Sodium, 135-145mEq/L; potassium, 3.5-5mEq/L; calcium, 8.1–10.4 mg/
dL; magnesium, 1.6–2.4mg/dL.
Genetic analysis
DNA samples were obtained from 38 out of the 41 patients with long QTc. In 3 patients the
DNA quality precluded genetic analysis and we could not obtain a second DNA sample from
them as they had died by the time we performed the genetic analysis. Moreover, we obtained
DNA sample from 9 patients with no QTc prolongation.
DNA isolation. Genomic DNA was extracted from whole blood using the Chemagic
MSM system I (Chemagic human blood). The concentration was checked using a Qubit 2.0
Fluorometer (Life Technologies) and purity was evaluated by measuring the 260/280 absor-
bance ratios (~ 1.8) using a NanoDrop1000 spectrophotometer (Thermo scientific). We used
1% agarose gel to confirm that that there was no DNA degradation.
Custom resequencing panel. The custom panel design included genes known to be
involved in SCD-related pathologies (SudDinCode1, Ferrer in Code). The genomic coordi-
nates of these genes were uploaded to the eArray web-based probe design tool (Agilent Tech-
nologies, Inc.). All isoforms described in the UCSC browser were included in the design. The
biotinylated cRNA probe solution was manufactured by Agilent Technologies and provided as
capture probes. The final size was 680 kbp of encoding regions and UTR boundaries. The
coordinates of the sequence data is based on NCBI build 37 (UCSC hg19).
A 24-gene panel of genes associated with arrhythmogenic cardiac diseases was used: ANK2,
CACNA1C, CACNB2, CASQ2, CAV3, DES, DSC2,DSG2,DSP, GPD1L, HCN4, JUP, KCNE1,
KCNE2, KCNH2, KCNJ2, KCNQ1, LMNA, PKP2, PRKAG2, RYR2, SCN4B, SCN5A and TGFB3.
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The technical characteristics of the NGS sequencing were: call rate 30X (99.8%), the
remaining 0.2% of the genome was sequenced by conventional Sanger Sequencing. Sensibility
and specificity (SNPs and small indels) were both 100%.
Bioinformatics analysis. Our secondary bioinformatics process includes a first-step that
trims the FAST-Q files originated by the MiSeq platform using a method developed by Gen-
diag.exe. The trimmed reads are then mapped with GEM II. The output from the mapping
step is combined and sorted, and uniquely and properly mapping read pairs are selected.
Finally, the cleaned BAM file is annotated using SAMtools v.1.18, GATK v2.4, and an ad hoc
method developed to generate the first raw VCF files. Variants are annotated with dbSNP IDs
[11]; Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA and
the 1000 Genomes browser[12], in-home database IDs and Ensemble information, where
available. Exome Aggregation Consortium (ExAC) was also consulted.
An algorithm developed by Gendiag.exe was used to determine the pathogenicity of the
detected variants according to the following criteria: variants with minor allele frequency
(MAF) <1% in the general population and the status of “probably damaging” in Provean and
Mutation Taster2 prediction were considered as rare/uncommon variants. The potential path-
ogenicity of missense variants was evaluated in silico using Provean and Mutation Taster2[13].
The performance of Provean is comparable to popular tools such as SIFT or PolyPhen-2[14,
15]. As supplemental data we used a UniProt database to consult the level of conservation
between different species [16]. An in-house database of variants was used as an internal
control.
Rare genetic variants in genes related to long QT syndrome, and variants of uncertain sig-
nificance (VUS) were confirmed by Sanger Sequencing.
Statistical analysis
Continuous variables were expressed as the mean ± standard deviation, and categorical vari-
ables were expressed as percentages. Differences between two related samples were evaluated
using a Paired-Samples T-test. We compared groups of continuous variables using ANOVA
and of categorical variables using the χ2-test. A P-value of<0.05 was considered statistically
significant.
Survival analysis was conducted using the Log Rang Test and Kaplan-Meyer by software R
(version 2.12).
Statistical analyses were performed using SPSS Statistics for Windows, Version 19.0 (IBM
Corp. Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM
Corp) and R (http://r-project.org).
Results
Hemodialysis-related changes in QTc and prognostic implications
We recruited a total of 111 patients undergoing regular hemodialysis, of which 70 had normal
QTc (63.1%; NNQTc), 24 had long QTc only after dialysis (21.6%; NLQTc), 8 had long QTc
only before dialysis (7.2%;, LNQTc) and 9 had long QTc both before and after dialysis (8.1%;
LLQTc). The average age was 66.27 (63.44–69.1), and 81/111 (73%) were male. We observed
no significant differences between the four groups in terms of age (p = 0.24), gender (p = 0.78),
diabetes (p = 0.82) or hypertension (p = 0.24) (Table 1, Table 2 and S1 Table).
The potassium and magnesium levels decreased significantly following HD in the four
groups (Table 3 and Table 4). Potassium levels were within normal range in pre-dialysis
(except for LLQTc group) and decreased to a value below the normal range in post-dialysis.
Magnesium levels were above the normal range in pre-dialysis and decreased to the normal
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range in post-dialysis. Calcium levels increased significantly after HD in all groups except
NLQTc group, although the values were within normal range in all groups. Sodium levels after
HD were not significantly different to those before HD in any group, and were also within the
normal rang.
We found no significant differences in electrolyte levels between the four groups, except for
post-dialysis sodium (p = 0.017) (S2 Table).
Mortality: Overall, 30.63% of patients died during the study, with patients with long QTc
having higher mortality than the control group (Table 1, Table 2 and S3 Table). The highest
mortality was observed in group 4 (LLQTc; 66.66%) followed by group 3 (LNQTc; 62.5%) and
group 2 (NLQTc; 37.5%). The lowest mortality was observed in patients in group 1 (NNQTc;
20%). QTc was significantly longer, both pre- and post- HD, among patients who died during
follow-up than among those who survived (S4 Table). After Log Rank analysis (Table 5) no sig-
nificant differences were identified (p = 0.144) however focusing on the Kaplan-Meyer curve
Table 1. Basic characteristics of the entire cohort and of the sequencing group.
Overall NNQTc NLQTc LNQTc LLQTc P-value
Variable unit 111 dialysis patients
Sample size N (%) 111 (100%) 70 (63.1%) 24 (21.6%) 8 (7.2%) 9 (8.1%)
Diabetes N (%)  32 (30.5%) 20 (29.4%) 8 (38.1%) 2 (28.6%) 2 (22.2%) 0.82
Hypertension N (%)  88 (83.8%) 58 (85.3%) 15 (71.4%) 6 (85.7%) 9 (100%) 0.24
Age (years old) Mean (95%
CI)
66.27 (63.44–69.1) 64.27 (60.38–68.17) 68.17 (62.41–73.93) 68.88 (61.6–78.14) 73.56 (66.89–80.22) 0.24
Male Gender N (%) 81 (73%) 51 (72.90%) 17 (70.80%) 7 (87.50%) 6 (66.70%) 0.78
QTc before
HD
(ms)
Mean (95%
CI)
426.05 (419.14–
432.95)
409.44 (402.28–416.6) 435.5 (426.72–444.28) 481.38 (471.58–
491.18)
480.78 (468.08–
493.49)
QTc after HD
(ms)
Mean (95%
CI)
440.66 (432.54–
448.78)
416.74 (411.24–
422.25)
493.54 (478.32–
508.76)
434 (412.15–455.85) 491.56 (477.67–
505.45)
Deaths N (%) 34 (30.63%) 14 (20%) 9 (37.5%) 5 (62.5%) 6 (66.6%) 0.008
LVEF Mean (95%
CI)
55.73 (53.62–57.83) 56.46 (53.83–59.09) 55.57 (50.49–60.64) 50 (31.9–68.1) 54 (48.26-58-74) 0.59
https://doi.org/10.1371/journal.pone.0200756.t001
Table 2. Basic characteristics of the entire cohort and of the sequencing group.
Overall NNQTc NLQTc LNQTc LLQTc P-value
Variable Unit 47 patients sequenced by NGS
Sample size N 47 9 23 6 9
Diabetes N (%) † 10 (27.02%) 1 (12.5%) 7 (35%) 0 2 (22.2%) 0.45
Hypertension N (%) † 30 (73.17%) 7 (87.5%) 14 (70%) 4 (80%) 9 (100%) 0.14
Age (years old) Mean (95%
CI)
68.32 (64.67–71.97) 63.56 (53.99–73.12) 67.65 (61.73–73.58) 70.17 (58.07–82.27) 73.56 (66.89–80.22) 0.25
Male Gender N (%) 30 (73.2%) 7 (77.8%) 17 (73.9%) 5 (83.3%) 6 (66.7%) 0.86
QTc before HD
(ms)
Mean (95%
CI)
440.49 (428.65–
452.33)
386 (357.01–414.99) 436 (426.87–445.13) 479 (466.01–491.99) 480.78 (468.07–
493.49)
QTc after HD (ms) Mean (95%
CI)
470.57 (457.37–
483.78)
414.89 (401.41–
428.37)
494.52 (478.73–
510.32)
430.84 (400.93–
460.7)
491.56 (477.66–
505.45)
Ms, milliseconds; NNQTc, NORMAL-NORMAL QTc; NLQTc, NORMAL-LONG QTc; LNQTc, LONG-NORMAL QTc; LLQTc, LONG-LONG QTc.
 Data available for 68, 21, 7 and 9 patients from the NNQTc, NLQTc, LNQTc and LLQTc groups, respectively.
† Data available for 8, 20, 5 and patients from the NNQTc, NLQTc, LNQTc and LLQTc groups, respectively.
https://doi.org/10.1371/journal.pone.0200756.t002
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the NNLQTc group showed higher survival than the groups with long QTc pre or post-HD.
Additionally the groups of NLQTc and LNQTc showed the lower survival (Fig 1).
Relationship between rare genetic variants in long QT syndrome genes and
changes in QTc induced by hemodialysis
We sequenced a total of 47 patients, as follows: 9 patients from NNQTc group, 23 patients
from NLQTc, 6 patients from LNQTc group, and 9 patients from LLQTc group. It was not
possible to sequence one patient from NLQTc group, and two patients from LNQTc group
due to poor DNA quality and the inhability of obtaining a new DNA sample (they died before
the genetic testing was performed) (Table 1 and Table 2).
Potentially pathogenic variants. Ultra-sequencing genetic analysis identified five rare
variants in genes related with long QT syndrome in five patients from the NLQTc group (Fig
2, Table 6 and Table 7). Index case 83 carried a private variant (KCNH2_p.P310S) not previ-
ously reported or identified in any of the available variant databases. Two unrelated patients
(index cases 76 and 84) carried a variant (KCNQ1_p.K393N) that had previously been reported
to be associated with long QT syndrome (CM078293), although via a different nucleotide
change (cytosine, not a thymine). We identified a variant in the SCN5A gene (SNC5A_p.
L461V) in case 86, previously associated with sudden adult death syndrome[17, 18]. Finally,
we detected a variant (KCNE1_p.R67C) in index case 94 that had previously been reported as
being associated with long QT syndrome [17].
Table 3. Electrolyte levels of the entire cohort.
111 dialysis patients
Variable NNQTc (N = 70) NLQTc (N = 24) LNQTc (N = 8) LLQTc (N = 9)
Pre-HD Post-HD P-Value Pre-HD Post-HD P-Value Pre-HD Post-HD P-Value Pre-HD Post-HD P-Value
Sodium 138.97
(138.26–139.68)
139.01
(138.62-139-4)
0.858 139.13
(137.92–140.33)
139.25
(138.21–140.29)
0.845 137.5
(134.60-140-40)
136.86
(135.4–138.31)
0.744 137.89
(135.63–140.14)
138.22
(136.74–139.7)
0.74
Potassium 4.96 (4.75–5.17) 3.12 (3.03–3.22) P < .001 4.9 (4.56–5.24) 3.06 (2.92–3.2) P < .001 4.48 (3.62–5.33) 2.97 (2.67–3.28) P < .001 5.18 (4.43–5.93) 3.16 (2.86–3.46) P < .001
Calcium 8.65 (8.51–8.78) 8.93 (8.8–9.06) P < .001 8.62 (8.27–8.98) 8.89 (8.71–9.07) 0.109 8.4 (7.63–9.17) 9.23 (8.4–10.06) 0.012 8.36 (7.83–8.88) 8.94 (8.49–9.4) 0.002
Magnesium 2.51 (2.4–2.62) 2.13 (2.08–2.17) P < .001 2.43 (2.28–2.58) 2.13 (2.05–2.2) P < .001 2.35 (2.09–2.61) 2.07 (1.89–2.25) 0.002 2.4 (1.91–2.89) 2.02 (1.8–2.24) 0.022
https://doi.org/10.1371/journal.pone.0200756.t003
Table 4. Electrolyte levels of the sequenced groups.
Variable NNQTc (N = 9) NLQTc (N = 23†) LNQTc (N = 6 ††) LLQTc (N = 9)
Pre-HD Post-HD P-
Value
Pre-HD Post-HD P-
Value
Pre-HD Post-HD P-
Value
Pre-HD Post-HD P-
Value
Sodium 140.11
(137.96–
142.27)
140.11
(138.81–
141.41)
1 139.09
(137.82–
140.35)
139.3
(138.23–
140.38)
0.742 139
(136.8–
141.2)
137
(134.68–
139.32)
0.047 137.89
(135.63–
140.14)
138.22
(136.74–
139.7)
0.74
Potassium 4.83 (4.18–
5.48)
3.03 (2.78–
3.29)
P <
.001
4.87 (4.52–
5.22)
3.05 (2.91–
3.2)
P <
.001
4.57 (3.31–
5.82)
3.04 (2.58–
3.5)
0.003 5.18 (4.43–
5.93)
3.16 (2.86–
3.46)
P <
.001
Calcium 8.61 (8.23–
8.99)
8.91 (8.62–
9.2)
0.097 8.6 (8.23–
8.96)
8.89 (8.7–
9.07)
0.098 8.35 (7.21–
9.49)
8.9 (7.8–9.8) 0.065 8.36 (7.83–
8.88)
8.94 (8.49–
9.4)
0.002
Magnesium 2.83 (2.45–
3.22)
2.22 (2.12–
2.33)
0.003 2.41 (2.26–
2.57)
2.13 (2.05–
2.2)
P <
.001
2.37 (2–
2.73)
2.12 (1.85–
2.39)
0.003 2.4 (1.91–
2.89)
2.02 (1.81–
2.23)
0.022
† 22 available patients in potassium and magnesium levels.
†† 5 available patients in all the electrolyte levels. Sodium and potassium levels are expressed in mEq/L and calcium and magnesium levels are expressed in mg/gL.
NNQTc, NORMAL-NORMAL QTc; NLQTc, NORMAL-LONG QTc; LNQTc, LONG-NORMAL QTc; LLQTc, LONG-LONG QTc. Values expressed as Mean (95%-
CI).
P value<0.05.
https://doi.org/10.1371/journal.pone.0200756.t004
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Variants of uncertain significance. Analysis of the 24 genes detected 20 common and
uncommon variants in 16 patients (34.04%) (S5 Table), 11 of which (69%) were indels and 5
(31%) were single-point variants. We observed variants of uncertain significance in 7 patients
with NNQTc, 6 with NLQTc, 3 with LNQTc and 4 with LLQTc. We identified uncommon
variants in DSP, JUP, CACNB2, RYR2 and CACNA1C (2 cases) genes. Two cases with uncom-
mon variants (index cases 10 and 102) carried the common rs17133512 variant in DSP. We
were unable to identify any uncommon variants in 31 cases.
Discussion
For the past four decades, patients who are on renal replacement therapy have been known to
have significant cardiovascular risk[19]. Most studies that have explored the basis of this risk
have focused on fluctuations in blood ion levels as a result of HD, and their relation with
increased QTc following HD. We have observed similar post-HD variations in ion levels as
previously published[20]. However, the correlations of these ion levels with QTc are a matter
of controversy. While Howse et al.[21], did not identify a correlation, Alabd et al.[9] reported a
correlation between post-dialysis QTc and a decrease in serum levels of potassium and magne-
sium after dialysis.
In order to shed some light in this issue, we have investigated the QTc duration before and
after HD and included genetic analysis in patients with prolonged QTc interval. We identified
twenty-four patients (21.6%) who had a prolonged QTc interval only after the HD session.
This percentage increased to 29.7% when we added those patients with long QTc before and
after HD (groups NLQTc and LLQTc together), and to 36.9% when we added those patients
with long QTc before HD (LNQTc, NLQTc and LLQTc). These data are very similar to those
published by Genovesi et al. in a cohort of 122 patients, in which they reported an incidence of
QTc prolongation of 36% in patients on HD, as measured before, during and after dialysis[22].
Similar to previous studies, the length of the QTc interval was not associated with gender, age
or hypertension[20]. In contrast to other reports, the QTc interval in our cohort was not asso-
ciated with the presence of diabetes [23].
We identified a clear correlation between the presence of a long QTc interval and mortality
in patients undergoing HD. To our knowledge, this is the first report of an association between
QTc interval and mortality in HD patients. Accordingly, those patients who died during the
study showed a higher QTc both pre- and post-HD than the surviving patients, which indi-
cates that a higher QTc value is an indicator or a bad prognosis in HD patients.
Genetic analysis of the main LQTS genes enabled the identification of five potentially path-
ogenic variants, which may be associated with prolongation of the QTc interval, in patients
with prolonged QTc interval only after HD (NLQTc group). While we were unable to perform
segregation studies, the high level of conservation between species indicates that these
Table 5. Kaplan-Meier survival analysis.
Group N 1 year 3 years 5 years 10 years P-value
NNQTc 70 100% 95,1%±2,8% 77,5%±6,3% 69%±8% 0,144
NLQTc 24 95,8%±4,1% 86,8%±7,1% 71,7%±9,9% 55,1%±11,3%
LNQTc 8 87,5%±11,7% 62,5%±17,1% 50%±17,7% 25%±19,8%
LLQTc 9 88.9%±10,57% 76,2%±14,8% 63,5%±16,9% 42,3%±20,6%
NNQTc: QTc interval normal pre-HD and post-HD; NLQTc: QTc interval normal pre-HD and long post-HD; LNQTc: QTc interval long pre-HD and normal post-HD;
LLQTc: QTc interval long pre-HD and post-HD. N: number of patients included in the corresponding group. P-value obtained from a Chi-squared test.
https://doi.org/10.1371/journal.pone.0200756.t005
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nucleotide changes may have an important role in protein function (Fig 3). Supporting this
potential pathogenic role, in silico analysis also predicted a deleterious effect.
In addition, we identified a large number of variants of unknown significance (20 variants,
observed in 16 of 47 cases), of which 6 were uncommon. The role of variation in these genes in
patients with ESRD merits further studies.
The considerably higher frequency of variants in sodium and potassium channels in this
patient group compared to the general population is intriguing. Gene expression databases
Fig 1. Kaplan-Meier curves for the 4 groups. NNQTc: QTc interval normal pre-HD and post-HD; NLQTc: QTc interval normal pre-HD and long post-HD; LNQTc:
QTc interval long pre-HD and normal post-HD; LLQTc: QTc interval long pre-HD and post-HD.
https://doi.org/10.1371/journal.pone.0200756.g001
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indicate that potassium channels (KCNQ1, KCNH2 and KCNE1 genes) are expressed in renal
cells (GTEX and the human protein atlas database). The function of basolateral Kv7.1
(KCNQ1) within the various segments of the nephron is still to be determined. However, these
channels could certainly be responsible for recycling K+ across the basolateral membrane, and
for maintaining an ion potential gradient, which serves to drive Na+ secretion in the nephron
[24]. Additionally, it seems likely that Kv7.1 plays a role in K+ reabsorption, in the context of a
low-K+ diet for example[25]. The pore-forming partner(s) of KCNE1 and the role of the
respective channel complexes in the kidney remain unknown [26]. Finally, KCNH2 is also
expressed in the kidney, although the function of its product, Kv11.1, has not yet been studied
in this organ. This novel mutation in KCNH2 would be a good candidate variant to test func-
tion in-vitro studies to elucidate their possible pathogenic role.
Fig 2. Forward and reverse electropherograms of the uncommon variants identified. A: KCNQ1_p.K393N; B: KCNH2_p.P310S; C: SCN5A_p.L461V; D:
KCNE1_p.R67C.
https://doi.org/10.1371/journal.pone.0200756.g002
Table 6. Description of the five uncommon variants identified, plus available clinical data. Exome Sequencing Project and ExAC.
Index
Case
Gene Isoform SNP HGMD Protein
change
cDNA
change
MAF (%)
EA/All
ExAC (%) Disease PolyPhen2 Condel
76 KCNQ1 NM_000218.2 rs12720457 - p.Lys393Asn c.1179G>T 0.0814/
0.0692
0.1098 LQTS Possibly damaging
(0.770)
Neutral
(0.462)
83 KCNH2 NM_000238.3 - - p.Pro310Ser c.928C>T - - - Benign (0.112) Neutral
(0.018)
84 KCNQ1 NM_000218.2 rs12720457 - p.Lys393Asn c.1179G>T 0.0814/
0.0692
0.1098 LQTS Possibly damaging
(0.770)
Neutral
(0.462)
86 SCN5A NM_198056.2 rs41313697 CM061953 p.Leu461Val c.1381T>G 0.0241/0.294 0.1163 SADS Benign (0.08) Neutral
(0.392)
94 KCNE1 NM_000219.4 - CM097703 p.Arg67Cys c.199C>T - 2.473.10–
3
LQTS Probably damaging
(1)
Deleterious
(1)
https://doi.org/10.1371/journal.pone.0200756.t006
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Conclusions
In conclusion, we provided evidence that the presence of long QTc interval in patients, who
are undergoing dialysis, may be an indicator of risk for SCD. We did not observe a relationship
between changes in electrolyte levels and the increment in QTc observed in some patients fol-
lowing HD. In fact, despite using an ion-balanced hemodialysis bath, we observed similar
Table 7. Description of the five uncommon variants identified, plus available clinical data. Exome Sequencing Project and ExAC.
Index
Case
Gender Age QTc pre/post Diabetes Hypertension Status Cause of death General etiology Specific etiology
76 Male 74 440/626 No Yes Death Unknown Vascular Nephroangiosclerosis and/or ischemic
nephropathy
83 Male 67 453/474 Yes No Death Cardiac arrest Vascular Nephroangiosclerosis
84 Male 43 420/480 Yes Yes HD - Systemic Nephropathy diabetic
86 Female 85 429/469 Yes Yes HD - Vascular Nephroangiosclerosis and nephropathy diabetic
94 Female 80 460/461 No Yes Death Cardiac arrest Vascular Nephroangiosclerosis
Abbreviations: Age is expressed in years. MAF: minor allele frequency; EA: European American; SNP: single nucleotide polymorphism. ExAC: Exome Aggregation
Consortium, Cambridge, MA (URL: http://exac.broadinstitute.org) [(March, 2017) accessed]. SADS: Sudden adult death syndrome.
https://doi.org/10.1371/journal.pone.0200756.t007
Fig 3. Sequence alignment for each variant in different species. The position of the first amino acid of each sequence is indicated on the left, and the
Uniprot reference for each protein is shown on the right. A: KCNQ1_p.K393N; B: KCNH2_p.P310S; C: SCN5A_p.L461V; D: KCNE1_p.R67C.
https://doi.org/10.1371/journal.pone.0200756.g003
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changes in electrolytes following HD to those previously reported. This question the relevance
of these electrolytes changes for prolongation of the QT interval in HD.
The presence of a prolonged QT interval was associated with the identification of patho-
genic genetic variants in ion channels, especially in those ESRD patients who presented with a
prolonged QT interval only after HD (NLQTc group). In addition, 3 out of 5 individuals in
this group died suddenly. This raises the hypothesis that there may be a genetic predisposition
to sudden cardiac death which may be identified by electrocardiographic and/or genetic
investigation.
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